Article Text

Long-term use and cost-effectiveness of secondary prevention drugs for heart disease in Western Australian seniors (WAMACH): a study protocol
  1. Anthony S Gunnell1,
  2. Matthew W Knuiman1,
  3. Elizabeth Geelhoed1,
  4. Michael S T Hobbs1,
  5. Judith M Katzenellenbogen2,
  6. Joseph Hung3,
  7. Jamie M Rankin4,
  8. Lee Nedkoff1,
  9. Thomas G Briffa1,
  10. Michael Ortiz5,
  11. Malcolm Gillies6,
  12. Anne Cordingley7,
  13. Mitch Messer8,
  14. Christian Gardner1,
  15. Derrick Lopez2,
  16. Emily Atkins1,
  17. Qun Mai9,
  18. Frank M Sanfilippo1
  1. 1School of Population Health, The University of Western Australia, Crawley, Western Australia, Australia
  2. 2Western Australian Centre for Rural Health, The University of Western Australia, Crawley, Western Australia, Australia
  3. 3School of Medicine & Pharmacology, Sir Charles Gairdner Hospital Unit, The University of Western Australia, Nedlands, Western Australia, Australia
  4. 4Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia
  5. 5St Vincent's Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia
  6. 6MedicineInsight, NPS MedicineWise, Sydney, New South Wales, Australia
  7. 7Consumer and Community Advisory Council, School of Population Health, The University of Western Australia, Crawley, Western Australia, Australia
  8. 8Health Consumers’ Council (WA) Inc., Perth, Western Australia, Australia
  9. 9Clinical Modelling Unit, Western Australian Department of Health, Perth, Western Australia, Australia
  1. Correspondence to Dr Anthony S Gunnell; anthony.gunnell{at}uwa.edu.au

Abstract

Introduction Secondary prevention drugs for cardiac disease have been demonstrated by clinical trials to be effective in reducing future cardiovascular and mortality events (WAMACH is the Western Australian Medication Adherence and Costs in Heart disease study). Hence, most countries have adopted health policies and guidelines for the use of these drugs, and included them in government subsidised drug lists to encourage their use. However, suboptimal prescribing and non-adherence to these drugs remains a universal problem. Our study will investigate trends in dispensing patterns of drugs for secondary prevention of cardiovascular events and will also identify factors influencing these patterns. It will also assess the clinical and economic consequences of non-adherence and the cost-effectiveness of using these drugs.

Methods and analysis This population-based cohort study will use longitudinal data on almost 40 000 people aged 65 years or older who were hospitalised in Western Australia between 2003 and 2008 for coronary heart disease, heart failure or atrial fibrillation. Linking of several State and Federal government administrative data sets will provide person-based information on drugs dispensed precardiac and postcardiac event, reasons for hospital admission, emergency department visits, mortality and medical visits. Dispensed drug trends will be described, drug adherence measured and their association with future all-cause/cardiovascular events will be estimated. The cost-effectiveness of these long-term therapies for cardiac disease and the impact of adherence will be evaluated.

Ethics and dissemination Human Research Ethics Committee (HREC) approvals have been obtained from the Department of Health (Western Australian #2011/62 and Federal) and the University of Western Australia (RA/4/1/1130), in addition to HREC approvals from all participating hospitals. Findings will be published in peer-reviewed medical journals and presented at local, national and international conferences. Results will also be disseminated to consumer groups.

  • CARDIOLOGY
  • CLINICAL PHARMACOLOGY
  • HEALTH ECONOMICS

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: